Opioid use disorder and COVID-19: Implications for policy and practice

JAAPA. 2021 Jun 1;34(6):1-4. doi: 10.1097/01.JAA.0000742976.14811.36.

Abstract

Preliminary data suggest that opioid-related overdose deaths have increased subsequent to COVID-19. Despite national support for expanding the role of physician assistants (PAs) and NPs in serving patients with opioid use disorder, these clinicians are held to complex and stringent regulatory barriers. COVID-19 triggered significant changes from regulatory and federal agencies, yet disparate policies and regulations persist between physicians and PAs and NPs. The dual epidemics of COVID-19 and opioid use disorder highlight the inadequate infrastructure required to support patients, communities, and clinicians, and may serve as the catalyst for eliminating barriers to care.

MeSH terms

  • Buprenorphine / therapeutic use
  • COVID-19 / epidemiology*
  • COVID-19 / prevention & control
  • Drug Prescriptions
  • Health Policy / legislation & jurisprudence
  • Health Services Accessibility / legislation & jurisprudence*
  • Humans
  • Legislation, Drug
  • Narcotic Antagonists / therapeutic use
  • Nurse Practitioners / legislation & jurisprudence
  • Opioid Epidemic
  • Opioid-Related Disorders / drug therapy*
  • Opioid-Related Disorders / epidemiology*
  • Physician Assistants / legislation & jurisprudence
  • Physicians / legislation & jurisprudence
  • SARS-CoV-2
  • Telemedicine
  • United States / epidemiology

Substances

  • Narcotic Antagonists
  • Buprenorphine